Abstract:Glucagon-secreting pancreatic a-cells play pivotal roles in the development of diabetes. Glucagon promotes insulin secretion from I3-cells. However, the long-term effect of glucagon on the function and phenotype of I3-cells had remained elusive. In this study, we found that long-term glucagon intervention or glucagon intervention with the presence of palmitic acid downregulated I3-cell-specific markers and inhibited insulin secretion in cultured I3-cells. These results suggested that glucagon induced I3-cell dedifferentiation under pathological conditions. Glucagon blockage by a glucagon receptor (GCGR) monoclonal antibody (mAb) attenuated glucagon-induced I3-cell dedifferentiation. In primary islets, GCGR mAb treatment upregulated I3-cell-specific markers and increased insulin content, suggesting that blockage of endogenous glucagon-GCGR signaling inhibited I3-cell dedifferentia-tion. To investigate the possible mechanism, we found that glucagon decreased FoxO1 expression. FoxO1 inhibitor mimicked the effect of glucagon, whereas FoxO1 overexpression reversed the glucagon-induced I3-cell dedifferentiation. In db/db mice and I3-cell lineage-tracing diabetic mice, GCGR mAb lowered glucose level, upregulated plasma insulin level, increased I3-cell area, and inhibited I3-cell dedifferentiation. In aged I3-cell-specific FoxO1 knockout mice (with the blood glucose level elevated as a dia-betic model), the glucose-lowering effect of GCGR mAb was attenuated and the plasma insulin level, I3-cell area, and I3-cell dedif-ferentiation were not affected by GCGR mAb. Our results proved that glucagon induced I3-cell dedifferentiation under pathological conditions, and the effect was partially mediated by FoxO1. Our study reveals a novel cross talk between a- and I3-cells and is helpful to understand the pathophysiology of diabetes and discover new targets for diabetes treatment.NEW & NOTEWORTHY Glucagon-secreting pancreatic a-cells can interact with I3-cells. However, the long-term effect of gluca-gon on the function and phenotype of I3-cells has remained elusive. Our new finding shows that long-term glucagon induces I3-cell dedifferentiation in cultured I3-cells. FoxO1 inhibitor mimicks whereas glucagon signaling blockage by GCGR mAb reverses the effect of glucagon. In type 2 diabetic mice, GCGR mAb increases I3-cell area, improves I3-cell function, and inhibits I3-cell de-differentiation, and the effect is partially mediated by FoxO1.

Glucagon Receptor Antagonism Promotes the Production of Gut Proglucagon-Derived Peptides in Diabetic Mice.

Glucagon Receptor Antagonist Upregulates Circulating GLP-1 Level by Promoting Intestinal L-cell Proliferation and GLP-1 Production in Type 2 Diabetes

Antagonistic Glucagon Receptor Antibody Promotes Α-Cell Proliferation and Increases Β-Cell Mass in Diabetic Mice

Glucagon Acting at the GLP-1 Receptor Contributes to β-Cell Regeneration Induced by Glucagon Receptor Antagonism in Diabetic Mice

115-LB: Liver-Derived FGF21 Mediates the Promoting Effect of Glucagon Receptor Antagonism on Beta-Cell Regeneration in Type 2 Diabetic Mice

Γ-Aminobutyric Acid Modulates Α-Cell Hyperplasia but Not Β-Cell Regeneration Induced by Glucagon Receptor Antagonism in Type 1 Diabetic Mice

Pro--cell-derived -cells contribute to -cell neogenesis induced by antagonistic glucagon receptor antibody in type 2 diabetic mice

Glucagon receptor antagonism increases mouse pancreatic δ-cell mass through cell proliferation and duct-derived neogenesis

Combination of GLP-1 Receptor Activation and Glucagon Blockage Promotes Pancreatic Β-Cell Regeneration in Situ in Type 1 Diabetic Mice

Glucagon Potentiates Insulin Secretion Via β-Cell GCGR at Physiological Concentrations of Glucose

Glucagon Potentiates Insulin Secretion Via Beta-Cell Gcgr At Physiological Concentrations Of Glucose

Glucagon receptor monoclonal antibodies: A new strategy for diabetes pharmacotherapy

Glucagon Switches between GLP-1 and Glucagon Receptors in Normal and Hyperglycemic Mice

Myeloid-Derived Growth Factor Promotes Intestinal Glucagon-Like Peptide-1 Production in Male Mice with Type 2 Diabetes.

Fatty acid β‐oxidation and mitochondrial fusion are involved in cardiac microvascular endothelial cell protection induced by glucagon receptor antagonism in diabetic mice

Glucagon receptor blockage inhibits ?-cell dedifferentiation through FoxO1

Crispr-Cas9 Mediated Complete Deletion of Glucagon Receptor in Mice Display Hyperglucagonemia and Α-Cell Hyperplasia.

Disruption of the Glucagon Receptor Increases Glucagon Expression Beyond Α-Cell Hyperplasia in Zebrafish

Intestinal glucagon-like peptide-1: A new player associated with impaired counterregulatory responses to hypoglycaemia in type 1 diabetic mice

Novel GLP-1 Analog Supaglutide Stimulates Insulin Secretion in Mouse and Human Islet Beta-Cells and Improves Glucose Homeostasis in Diabetic Mice.

The Identification of Novel Protein-Protein Interactions in Liver That Affect Glucagon Receptor Activity